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Introduction
Epithelial–stromal interactions, mediated by the extra-
cellular matrix, play a pivotal role in normal mammary gland
function [1]. These interactions, along with epithelial–
epithelial interactions, actively suppress the expression of
the preneoplastic phenotype in epithelial cells [2–7]. It is
now recognized that a specific environment is necessary
for tumorigenesis; indeed, it has been postulated that
cancer can be a physiological response to an abnormal
stromal environment (reviewed in [8–11]).
An abnormal stroma can be regarded as a classical
promoter in the terminology of carcinogenesis, in that the
dysfunction of normal epithelial–mesenchymal interactions
increases the probability that the preneoplastic lesion will
progress to malignancy. On the other hand, in the
terminology of development, the environment provided by
the abnormal stroma may be considered ‘permissive’ for
tumorigenesis by leading to the selection of cells with
altered survival characteristics.
Both these views signify that an aberrant stroma
predisposes tissue to cancer by increasing the frequency
with which an initiated cell proceeds to neoplasia, rather
than by increasing the frequency of initiation. Although few
studies have attempted to define the particular point at
which the stroma actively participates in multistep
carcinogenesis, several important concepts have been put
forward [12–14]. Importantly, normal stroma can efficiently
inhibit the expression of neoplastic characteristics of
tumor cells. Conversely, perturbations in the epithelial–
stromal interaction may accelerate the process of
carcinogenesis, especially since carcinogen exposure
elicits persistent phenotypic changes in stromal cells.
These non-neoplastic stromal effects induced by
carcinogens can be conducive to the expression of or to
the progression of preneoplastic phenotypes, just as
carcinoma-associated fibroblasts support malignant
behaviors. Together stromal alterations are likely to be
essential to the development of frank, neoplastic disease.
Understanding them requires additional experimental
models.
Among the many mediators of stromal–epithelial inter-
actions, the extracellular cytokine transforming growth
factor beta 1 (TGF-β) is perhaps one of the best studied,
and most perplexing. TGF-β has been widely implicated in
mammary epithelial growth (reviewed in [15]), in cancer
(reviewed in [16]), and in response to estrogen and
progesterone in breast cancer cells and the mammary
gland (reviewed respectively in [17,18]). As such, TGF-β
is a focus of research highlighted in these recent reports.
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Abstract
Although the stroma in which carcinomas arise has been previously regarded as a bystander to the
clonal expansion and acquisition of malignant characteristics of tumor cells, it is now generally
acknowledged that stromal changes are required for the establishment of cancer. In the present article,
we discuss three recent publications that highlight the complex role the stroma has during the
development of cancer and the potential for targeting the stroma by therapeutic approaches.
Keywords: breast, carcinogenesis, chemical carcinogen, radiation, stroma, transforming growth factor beta 134
Breast Cancer Research    Vol 7 No 1 Barcellos-Hoff and Medina
Recent studies in stromal–epithelial
interactions
Several noteworthy studies of stromal effects on carcino-
genesis have recently appeared in the literature. First,
Moses and colleagues have shown that TGF-β signaling in
fibroblasts modulates the growth and oncogenesis of
adjacent epithelia [19]. These studies used conditional
inactivation of the TGF-β type II receptor gene in
fibroblasts (Tgfβr2fspKO mice), which rapidly led to
development of intraepithelial neoplasia in prostate and
invasive squamous cell carcinoma of the forestomach, both
accompanied by increased abundance of stromal cells.
The authors suggest that this is due in part to the
dysregulation of hepatocyte growth factor (HGF). The
TGF-β signaling pathway, whether activated in epithelial
cells or in adjacent stromal fibroblasts, therefore does have
an inhibitory effect on epithelial proliferation. Loss of this
inhibitory pathway may facilitate progression to invasive
carcinoma in some tissues. The question of the initiating
events in the neoplasms and the growth autonomy of the
neoplasms were not addressed in these studies.
Second, an orthotopic xenograft breast model that uses
human fibroblasts to condition the mouse mammary gland
so that it supports growth of primary human breast
organoids was introduced by the Weinberg laboratory
[20]. Similar to the experiments of Parmar and colleagues
that demonstrated a novel method using reconstituted
mammary epithelium and mouse-derived or human-derived
fibroblasts in collagen gels as the transplanted material for
examining the growth of human mammary epithelium in
nude mice [21], these models provide another approach
to understanding important factors that play a regulatory
role in both normal and neoplastic development. The
‘humanized’ fat pads provided the necessary
microenvironment to promote outgrowths of remarkably
differentiated epithelial structures capable of at least
rudimentary secretory differentiation. The specific cellular
components of human stroma, in contrast to what is
contained in mouse stroma, therefore provided an
essential signal for growth and differentiation of normal
epithelial behavior. This model is an important addition to
the arsenal of the experimentalist since it provides a
means of recreating the critical physiological environment,
albeit in a mouse host, for human breast epithelium in the
context of at least a partial human stroma. Future models
in which the humanized fat pad is generated in the context
of a humanized bone marrow could further species-
specific interactions.
Equally notable in this study was that perturbation of
stromal signaling by human fibroblasts engineered to
overexpress active TGF-β or HGF promoted the
development of histologically malignant lesions from
ostensibly ‘normal’ human mammary epithelial cells. The
behavior of this one specimen is consistent with the
interpretation that this specimen contained occult initiated
cells. The different effect of TGF-β signaling on truly
normal cells versus initiated cells observed in this study
speaks to the stage-specific effects reported in both
human and mouse mammary models of progression
[22,23].
Where and when TGF-β is active in the mammary gland is
still fairly undefined due to multiple controls on its
bioavailability. In classic experiments by Silberstein and
Daniel to define the effects of TGF-β on the mammary
gland, pellets containing TGF-β were implanted in the
highly proliferative pubertal mouse mammary gland. This
implantation resulted in regression of the terminal
endbuds [24]. Interestingly, similar experiments during
early pregnancy showed little effect on the proliferating
alveolar epithelium. Two possibilities may explain these
differential effects. First, the epithelium is refractory to
TGF-β during pregnancy. However, recent studies
indicate that the epithelium is responsive to TGF-β during
this period since its depletion results in significantly
increased proliferation in the Tgfβ1 heterozygote
mammary gland [25]. In this case, there might exist a
maximum threshold for TGF-β function — thus, added
TGF-β (supplied by the implant) would have no discernible
effect. Alternatively, it may be that the effect of exogenous
TGF-β during puberty is mediated via the stroma. A recent
study using the same implant experimental design in
prepubertal heifers provides support for this possibility.
Short-term TGF-β exposure (<24 hours) resulted in
increased stromal proliferation and fibronectin mRNA
abundance, without affecting epithelial proliferation [26].
The experiments in humanized mammary gland, in which
fibroblasts producing TGF-β or HGF promoted malignant
progression in susceptible epithelium [20], also indicate
that stromal TGF-β acting on the epithelium in a paracrine
fashion may have very different effects on the epithelium
than autocrine sources (i.e. TGF-β-producing fibroblasts
stimulated proliferation rather than inhibited proliferation).
However, this differential effect may also be a function of
the developmental or premalignant state of the epithelial
cells. Consistent with this, loss of mammary stroma
responsiveness to TGF-β via expression of a dominant-
negative receptor resulted in increased mammary
epithelial branching and expression of HGF [27]. These
studies indicate that the tissue compartment source of
TGF-β is a significant factor in assessing how TGF-β may
contribute to breast composition and breast cancer risk.
A third study from the laboratories of Soto and
Sonnenschein suggest that the stroma is one of the
targets of the chemical carcinogen N-methylynitrosurea in
the rat mammary gland [28]. As shown with ionizing
radiation [29], exposing the rat mammary stroma to N-
methylynitrosurea promoted tumorigenesis of mammary35
epithelial cells that were not treated with the chemical
carcinogen. Interestingly, a similar but not identical
experiment using 7,12-dimethylbenzanthracene-treated
mouse mammary stroma did not promote tumorigenesis of
untreated TM10 preneoplastic mouse mammary
outgrowths [30]. In the case of ionizing radiation the cell
line COMMA-1D was used because it could either
generate a normal epithelial outgrowth or produce small
tumors in a normal stroma [31]. In the irradiated stroma,
the cells produced predominantly tumors that were quite
large and fast growing, indicating that radiation alters the
stroma in a manner that promoted the neoplastic potential.
Notably, TGF-β activation is induced by ionizing radiation
[32]. Differences between carcinogen action and the
effect on stroma and the host, in addition to differences in
the ‘initiated’ populations in each of these models, may
thus account for different outcomes, and remain to be
resolved. However, these studies emphasize that the
interactions between the epithelium and the stroma evolve
dynamically, and thus will require considerable study if
they are to be manipulated therapeutically.
Indeed, the mouse mammary gland is well suited for such
studies because of the ease of recombining the epithelium
and the stroma, and because of the availability of a wide
variety of engineered mouse models. For example, Jessani
and colleagues have recently used functional proteomic
techniques to show that the in vivo environment of the
mouse mammary fat pad cultivates the growth of human
breast cancer cells with distinct molecular and cellular
properties [33]. Man and colleagues examined the role of
a specific transcription factor, ets2, in the stroma using
transplantation of initiated cells into mammary fat pads of
mice that had altered ets2 activity [34]. Tumor growth was
decreased relative to the stroma of wild-type mice, which
was associated with increased p21Cip1 expression and
with decreased MMP-3 and MMP-9 mRNA expression.
Future research targeting stroma
therapeutically
Together, these recent studies underscore that the
stromal–epithelial interface is a critical mediator of
oncogenic potential. The heightened awareness of the
stroma as an active participant in carcinogenesis has led to
ideas for intervening in breast cancer progression by
manipulating the stroma [35–38]. Compared with the
multiple routes taken by cells to become cancers, the
response of tissues to cancer is relatively predictable.
Controlling the early stages of invasive cancer growth may
therefore be more readily achieved indirectly via the stroma.
As cancer progresses, it is clear that normal cells are
recruited by the tumor and are subverted in a manner that
warps the phenotype, sometimes resulting in persistent
phenotypic change (e.g. myofibroblasts, tumor
endothelium). In this scenario, the therapeutic potential
lies in the juxtaposition of novel events that may lead to
novel targets, such as the revelation of cryptic epitopes,
fetal protein forms, or matrikines [39]. Some stromal
targets (e.g. the induction of proteases, growth factors
and extracellular matrix proteins) are a reaction to the
disruption of tissue architecture by malignant cells, in a
manner akin to ‘the wound that does not heal’ [40]. Since
normal cells have a restricted repertoire of possible
responses, it is likely that there will be common events that
underpin the production of tumors that can be widely
targeted. Angiogenesis inhibitors are an excellent example
of the type of target that may be most suitable for
manipulation early in carcinogenesis, or as a
chemopreventative strategy [41]. Viewing the
opportunities for inhibiting cancer progression as a
dynamic process, in which tumor control may be mediated
by more than cell kill as a consequence of single and
multiple anticancer agent exposures, may uncover
additional tissue processes that are susceptible to
intervention.
To exploit these possibilities, we need to better
understand the dynamic interactions between the
epithelium and the stroma, and between cancer and the
stroma, which in turn will help define the windows of
opportunity in the stroma for cancer suppression and
repression. The recent development of stroma-specific
promoters for use in genetically engineered mouse
mammary models and the humanized mouse stroma
model provide additional experimental manipulations to
define these interactions. The recent publications in this
area are provocative evidence that manipulating stroma
may be of benefit in cancer treatment.
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